Australia markets closed
  • ALL ORDS

    7,325.80
    +8.30 (+0.11%)
     
  • ASX 200

    7,063.50
    +4.90 (+0.07%)
     
  • AUD/USD

    0.7735
    -0.0020 (-0.26%)
     
  • OIL

    63.27
    -0.19 (-0.30%)
     
  • GOLD

    1,777.60
    +10.80 (+0.61%)
     
  • BTC-AUD

    79,796.37
    -1,760.15 (-2.16%)
     
  • CMC Crypto 200

    1,385.25
    -6.46 (-0.46%)
     
  • AUD/EUR

    0.6455
    -0.0018 (-0.27%)
     
  • AUD/NZD

    1.0831
    +0.0026 (+0.24%)
     
  • NZX 50

    12,684.73
    +48.18 (+0.38%)
     
  • NASDAQ

    14,038.39
    +12.20 (+0.09%)
     
  • FTSE

    7,019.53
    +36.03 (+0.52%)
     
  • Dow Jones

    34,139.81
    +103.82 (+0.31%)
     
  • DAX

    15,459.75
    +204.42 (+1.34%)
     
  • Hang Seng

    28,969.71
    +176.57 (+0.61%)
     
  • NIKKEI 225

    29,683.37
    +40.68 (+0.14%)
     

Antidepressants Market to Touch USD 18.29 Billion by 2027; Growing Awareness about Mental Health Conditions to Fuel the Market: Fortune Business Insights™

Fortune Business Insights
·7-min read

Top Players Covered in the Antidepressants Market Research Report Are Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel), AstraZeneca (Cambridge, U.K), Pfizer Inc. (New York, U.S), Eli Lilly and Company (Indiana, U.S), H. Lundbeck A/S (Denmark, Europe), Bristol-Myers Squibb (New York, U.S), Merck & Co. Inc. (New Jersey, U.S), Janssen Pharmaceuticals (Beerse, Belgium), GlaxoSmithKline plc (Brentford, U.K) and other key market players.

Pune, India, March 08, 2021 (GLOBE NEWSWIRE) -- The global antidepressants market size is projected to reach USD 18.29 billion by 2027, exhibiting a CAGR of 2.9% during the forecast period. The skyrocketing demand for depression management drugs amid the COVID-19 pandemic will rapidly broaden the horizons of this market, observes Fortune Business Insights™ in its report. According to a joint study conducted by researchers from Boston University, Brown University, and the Hassenfeld Child Health Innovation Institute, depression symptoms were three times higher during the coronavirus-induced lockdown.

The sudden spike in the prevalence of anxiety and depressive tendencies among populations has created major shortages of essential antidepressants worldwide. In Canada, for instance, Pfizer’s anti-depressant, Nardil, went out of stock in June 2020 and Health Canada predicts that the drug shortage is likely to last till August 2021. Furthermore, the US Food and Drug Administration (FDA) revealed in June 2020 that the antidepressant Zoloft is facing huge shortages as the pandemic has disrupted pharmaceutical supply chains. The dramatic rise in the demand for depression medications and the consequent surge in sales enabled the market to showcase a prolific CAGR of 28.0% in 2020, reaching USD 14.93 billion in value.


Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/antidepressants-market-105017


Presence of Leading Market Players to Catalyze the Market in North America

North America is expected to dominate the antidepressants market share during the forecast period, backed by the strong presence and widespread operations of large pharmaceutical companies, such as Pfizer and Merck, in the US. These conglomerates, due to their sound financial health, are constantly engaged in the creation and launch of novel depression therapies, which has been the primary factor for the region’s apex position in this market. The North America market size stood at USD 6.00 billion in 2019.

In Europe, rising investments in clinical trials and huge funding for research & development activities will foster lasting growth of the regional market. On the other hand, Asia Pacific is set to present lucrative opportunities over the next decade as the increasing incidence of depression and anxiety disorders will stoke the adoption of anti-depressants.


Click here to get the short-term and long-term impacts of COVID-19 on this Market.

Please visit: https://www.fortunebusinessinsights.com/antidepressants-market-105017


Increasing Application of AI in Detecting Depression to Open Floodgates of Innovation

The employment of artificial intelligence (AI) in identifying depressive behaviors in individuals is paving new pathways for the market growth. Several startups, healthcare technology entities, and academic institutions have been AI-based algorithms, systems, and tools for depression. For example, Baltimore-based Sunrise Health, a startup incubated under Johns Hopkins Technology Ventures, has developed a system that uses AI-based predictive analytics to regulate patient activity and inhibit the onset of mental health breakdown episodes through support-group texting. On the other hand, California-based startup, Mindstrong Health, utilizes machine learning (ML) to aid the diagnosis and treatment of behavioral health disorders by leveraging data generated from smartphones.

In June 2020, psychiatry researchers at Stanford University developed an AI-based algorithm to study brainwave patterns specific to depression patients, aiming to identify which symptoms change with treatment in a more pinpointed manner. Thus, AI has displayed vast potential in enhancing the efficacy and accuracy of antidepressants, thereby brightening the outlook of this market.


Quick Buy - Antidepressants Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/105017


List of Key Companies Covered in this Market Report:

  • Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel)

  • AstraZeneca (Cambridge, U.K)

  • Pfizer Inc. (New York, U.S)

  • Eli Lilly and Company (Indiana, U.S)

  • H. Lundbeck A/S (Denmark, Europe)

  • Bristol-Myers Squibb (New York, U.S)

  • Merck & Co. Inc. (New Jersey, U.S)

  • Janssen Pharmaceuticals (Beerse, Belgium)

  • GlaxoSmithKline plc (Brentford, U.K)


Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/antidepressants-market-105017


Some major points from Table of Content:

  • Introduction

    • Market Scope

    • Market Segmentation

    • Market Methodology

    • Definitions and Assumptions

  • Executive Summary

  • Market Dynamics

    • Market Drivers

    • Market Restraints

    • Market Opportunities

  • Key Insights

    • Prevalence of Anxiety & Depression –Key Regions/Country

    • New Product Launch

    • Pipeline Analysis

    • Impact of COVID-19 on the Market

    • Key Industry Developments - Mergers, Acquisitions, and Partnerships

  • Global Antidepressants Market Analysis, Insights and Forecast, 2016-2027

    • Key Findings / Summary

    • Market Analysis, Insights and Forecast – By Drug Class

      • Selective Serotonin Reuptake Inhibitors (SSRIs)

      • Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)

      • Atypical Antidepressants

      • Tricyclic Antidepressants (TCAs)

      • Monoamine Oxidase Inhibitors (MAOIs)

      • Others

    • Market Analysis, Insights and Forecast – By Disorder

      • Major Depressive Disorder

      • Obsessive Compulsive Disorder

      • Generalized Anxiety Disorder

      • Panic Disorder

      • Others

    • Market Analysis, Insights and Forecast – By Distribution Channel

      • Hospital Pharmacy

      • Retail Pharmacy

      • Online Pharmacy

    • Market Analysis, Insights and Forecast – By Geography

      • North America

      • Europe

      • Asia Pacific

      • Latin America

      • Middle East & Africa

  • North America Market Analysis, Insights and Forecast, 2016-2027

    • Key Findings / Summary

    • Market Analysis, Insights and Forecast – By Drug Class

      • Selective Serotonin Reuptake Inhibitors (SSRIs)

      • Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)

      • Atypical Antidepressants

      • Tricyclic Antidepressants (TCAs)

      • Monoamine Oxidase Inhibitors (MAOIs)

      • Others

    • Market Analysis, Insights and Forecast – By Disorder

      • Major Depressive Disorder

      • Obsessive Compulsive Disorder

      • Generalized Anxiety Disorder

      • Panic Disorder

      • Others

    • Market Analysis, Insights and Forecast – By Distribution Channel

      • Hospital Pharmacy

      • Retail Pharmacy

      • Online Pharmacy

    • Market Analysis, Insights and Forecast – By Country

      • U.S.

        • By Disorder

          • Major Depressive Disorder

          • Obsessive Compulsive Disorder

          • Generalized Anxiety Disorder

          • Panic Disorder

          • Others

      • Canada

        • By Disorder

          • Major Depressive Disorder

          • Obsessive Compulsive Disorder

          • Generalized Anxiety Disorder

          • Panic Disorder

          • Others

Continued...


Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/antidepressants-market-105017


Have a Look at Related Reports:

Gene Therapy Market Size, Share & COVID-19 Impact Analysis, By Application (Oncology, Neurology, and Others), By Vector Type (Viral and Non-viral), By Distribution Channel (Hospitals, Clinics, and Others), and Regional Forecast, 2020-2027

Diabetes Treatment Devices Market Size, Share & Industry Analysis, By Product (Insulin Pens, Insulin Pumps, Insulin Jet Injectors, Insulin Syringes, Others), By Distribution Channel (Institutional Sales, Retail Sales) and Regional Forecast, 2019-2026

Hyaluronic Acid Based Dermal Fillers Market Size, Share and Industry Analysis By Crosslinking Type (Monophasic, Biphasic), By Application (Scar Treatment, Wrinkle Correction Treatment, Lip Enhancement, Restoration of Volume/ Fullness), By End User(Specialty & Dermatology Clinics, Hospitals & Clinics) and Regional Forecast, 2019 – 2026

Vitamin D Testing Market Size, Share and Industry Analysis By Product (25 -Hydroxy Vitamin D Testing, 1,25-Dihydroxy Vitamin D Testing, 24,25-Dihydroxy Vitamin D Testing), By Application (Clinical Testing, Research Testing), By End User (Diagnostic Laboratories, Hospitals & Clinics, Others), and Regional Forecast 2019-2026

Veterinary Imaging Market Size, Share & COVID-19 Impact Analysis, By Product Type (X-ray, Ultrasound, Computed Tomography Systems, Magnetic Resonance Imaging Systems, and Others); By Application (Neurology, Oncology, Cardiology, Gynecology, Orthopedics, and Others); By Animal Type (Livestock Animals and Companion Animals), by End User (Veterinary Hospitals, Diagnostic Imaging Centers, and Others), and Regional Forecast 2020-2027


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.


Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs


Press Release: https://www.fortunebusinessinsights.com/press-release/global-antidepressants-market-10543